IL-33R and IL-1RAcP fusion proteins
AssigneesVib Vzw, Universiteit Gent
InventorsRudi Beyaert, Harald Braun, Bart Lambrecht, Hamida Hammad
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel inhibitors of IL-33. More specifically, it relates to a fusion protein of the soluble IL-33 receptor with the soluble IL-1RAcP as inhibitor of IL-33 activity. The invention relates further to the use of the inhibitor in treatment of IL-33-related diseases such as, but not limited to, asthma, atopic dermatitis and psoriasis.
Claims4
A monomeric fusion protein comprising a soluble IL-33 receptor and a soluble IL-1RAcP, wherein the fusion protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:7.
A monomeric fusion protein comprising a soluble IL-33 receptor and a soluble IL-1RAcP, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:6.
Dependencies are inferred from the claim text.